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Background: Chronic constipation is frequent in children. The objective of this study is to compare the efficacy
and safety of PEG 4000 and lactulose for the treatment of chronic constipation in young children.
Methods: This randomised, double-blind study enrolled 88 young children aged 12 to 36 months, who were
randomly assigned to receive lactulose (3.3 g per day) or PEG 4000 (8 g per day) for four weeks. The primary
efficacy variable was stool frequency during the fourth week of treatment. Secondary outcomes were the number
and frequency of subjective symptoms associated with defecation at each visit.
Results: Stool frequency was comparable in the two groups at baseline (lactulose: 0.7 ± 0.5; PEG 4000: 0.5 ± 0.55).
Mean stool frequency increased from 0.70 ± 0.50 stools/day at baseline to 0.80 ± 0.41 at Week 4 in the lactulose
group and from 0.50 ± 0.55 to 1.10 ± 0.55 stools/day in the PEG 4000 group. A significant difference was observed
in the adjusted mean change from baseline, which was 0.15 stools/day in the lactulose group and 0.51 stools/day
in the PEG 4000 group, with a least-squares mean difference of 0.36 stools/day [95% CI: 0.16 to 0.56]. With respect
to secondary outcome variables, stool consistency and ease of stool passage improved more in the PEG 4000 group
(p = 0.001). The incidence of adverse events was similar in both groups, the majority of which were mild.
Conclusions: PEG 4000 has superior efficacy to lactulose for the treatment of chronic constipation in young
children and is well tolerated.
Trial registration: US National Institute of Health Clinical Trials database; study NCT00255372 first registered 17th
November 2005.
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Constipation is an extremely common problem in children
accounting for 3% of all visits to paediatric outpatient
clinics and up to as many as 25% of all visits to paediatric
gastroenterologists in the United States [1,2]. Nonetheless,
the prevalence of functional constipation in the community
is not known with any precision, and prevalence rates ran-
ging from 0.7% to 29.6% have been reported in the litera-
ture, with a median of 8.9% [3]. In Asian populations,
reported prevalence rates are at the higher end of the* Correspondence: suporn.tre@mahidol.ac.th
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article, unless otherwise stated.range, for example 29.6% in Hong Kong [4] and 24.9% in
Shanghai [5].
The occurrence of chronic constipation in children can
lead to significant abdominal pain, appetite suppression,
lowered self-esteem due to faecal incontinence, social isola-
tion, feelings of depression, school absenteeism and family
disruption [6]. Moreover, if constipation in children is not
adequately managed, it may persist into adulthood. On the
other hand, effective early treatment in children may pro-
vide a definitive cure [7,8].
Treatment goals are to produce soft, painless stools and
to prevent the reaccumulation of faeces [6], which can be
achieved through dietary modification, behavioural inter-
ventions, and the use of laxatives, or a combinationd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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lubricants, such as paraffin oil, osmotic laxatives, includ-
ing lactulose, sorbitol, magnesium hydroxide and poly-
ethylene glycol (PEG), and stimulant laxatives such as
senna or bisacodyl.
Polyethylene glycol (PEG, macrogol) is a polymer of
ethylene oxide units of variable molecular weight. Poly-
mers with a molecular weight of over 3000 are essentially
unabsorbed or metabolised in the intestine and are used
as osmotic laxatives, due to their high water binding cap-
acity [9]. Two PEG preparations, PEG 3350 (Glycolax®,
Miralax®, Braintree Laboratories Inc, Braintree, Mass,
USA, Transipeg® Bayer) and PEG 4000 (Forlax®, Ipsen,
France) have been developed for this purpose.
Although the superiority of PEG over other osmotic lax-
atives has been well documented in adults, the evidence
base is more restricted in paediatric populations. The
number of well-designed randomised, double-blind clin-
ical trials that have evaluated PEG in the management of
chronic constipation in children remains relatively limited,
and the number of subjects evaluated is low [10]. These
include two placebo-controlled studies of PEG 3350
[11,12], three studies comparing PEG 3350 to lactulose
[13-15], two comparing PEG 4000 to lactulose [16-18],
one comparing PEG 3350 to magnesium hydroxide [19],
two comparing PEG 4000 to magnesium hydroxide
[20,21] and two comparing PEG 3350 to liquid paraffin oil
[22,23]. The majority of these studies included older chil-
dren and little data is available in children younger than
three years of age. Further clinical trials would be helpful
to extend the available evidence base, in particular studies
performed in young children. The primary objective of the
present study was to compare the efficacy of PEG 4000 to
that of lactulose in the treatment of young children aged
between 12 to 36 months with chronic constipation.
Methods
This phase III randomised, double-blind, active-controlled,
parallel-group study was conducted in outpatients consult-
ing in two general hospitals in Thailand (Ramathibodi
Hospital, Mahidol University, Bangkok and Maharat
Nakhon Ratchasima Hospital, Nakhon Ratchasima) from
2004 to 2008. The study was registered in the Clinical
Trials database of the US National Institute of Health
under the study identifier NCT00255372.
Each patient underwent four study visits. At the screen-
ing visit (Visit 1; Week −2), inclusion criteria were verified
and demographic and clinical information was docu-
mented. The patient’s family was provided with dietary ad-
vice to restore normal bowel movements and with a diary
in which stool output was to be recorded. At the inclusion
visit (Visit 2; Week 0), if constipation had not resolved
through dietary modification, eligibility criteria were veri-
fied and the patient was randomised to one of the twotreatment groups. A new stool diary was provided. The
patients attended two follow-up visits (Visits 3 and 4;
Weeks 2 and 4) to document efficacy and safety of
treatment.
Patients
The study included young children aged between 12 to
36 months with a diagnosis of chronic functional consti-
pation based on a modification of the Rome II criteria for
infants and preschool children [24]. This was defined as
EITHER a stool frequency of ≤2 per week persisting for at
least three months OR the presence of pebble-like, hard
stools, painful defecation or faecal incontinence for at
least three months. Faecal incontinence was defined oper-
ationally as soiling of underclothes in children who had
already acquired toilet skills.
All patients were followed for two weeks (between Visits
1 and 2) following provision of dietary advice, and only
those children whose symptoms failed to improve during
this period were eligible. Children whose parents failed to
provide written informed consent were not eligible. Exclu-
sion criteria included the presence of organic bowel
disease, suspected gastrointestinal obstruction, a history of
GI surgery, any other condition or baseline finding that
might, in the opinion of the investigator, interfere with the
implementation or interpretation of the study, and a
history of hypersensitivity to the investigational drug or
related drugs.
In order to evaluate possible inclusion bias, each investi-
gator documented in a screening log all patients who were
considered eligible for the study but who were not in fact
enrolled. For each patient, the primary reason for exclu-
sion was recorded. Patients could be withdrawn from the
study if their parents requested discontinuation of treat-
ment because of lack of efficacy.
Treatment
Treatment was allocated using a randomisation list of
treatment allocation codes prepared by the contract re-
search organisation responsible for operational manage-
ment of the study. After confirmation of the eligibility
criteria, patients were randomised in a sequential order
within each centre. The randomisation list was kept confi-
dential in a safe and secure location until approval was
received for the study to be un-blinded for analysis.
Eligible subjects were randomly assigned to receive
either lactulose (3.3 g per day) or PEG 4000 (Forlax®; 8 g
per day) for a period of four weeks. These doses corres-
pond to the recommended doses for use in young children
provided in the prescribing information for these two laxa-
tives. Lactulose was provided as a 3.3 g sachet dissolved in
60 mL of water taken in the morning. A sachet of lactulose
placebo containing an inert powder (Glucidex IT38 and
saccharin) with the same flavour as lactulose was taken in
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solved in 60 mL of water taken in the morning, and an
identical sachet taken in the evening. All sachets were simi-
lar in size, colour, smell, taste and appearance in order to
ensure adequate blinding of the study medication. In the
event that a patient did not receive the study medication as
planned, the primary reason for this was documented in
the case report form.
Children with faecal impaction received an enema
(Unison®, sodium chloride 15% solution; 10 mL in one or
two doses) in order to empty the rectum before starting
the study treatment. Parents were permitted to give a
Unison® enema if their child failed to have a stool for
three days. Use of other laxatives or purgatives such as
milk of magnesia, mineral oil or ispaghula husk was not
permitted during this study.
Data collection
At the screening visit (Visit 1) and the inclusion visit
(Visit 2), the age and gender of the patient were recorded
and weight, height and vital signs measured. Information
was documented on medical and treatment history, and a
complete physical examination was performed. At the
follow-up visits (Visits 3 and 4), stool output during the
preceding two-week period were identified from the pa-
tient diary. The parents were asked about the occurrence
of potential adverse events.
Outcome measures
Stool frequency was determined for Weeks −1 (baseline),
1, 2 and 3 and 4 as the mean number of stools passed per
day for the seven days of the week. The primary efficacy
variable was stool frequency at Week 4. Secondary efficacy
measures were stool consistency, ease of stool passage and
the occurrence of subjective symptoms associated with
defecation, namely cramping, flatus and anal irritation at
each visit. Adverse events (AEs) were assessed from
discussion with the parents at Visits 3 and 4. Incidence of
AEs and serious AEs (SAEs) was documented over the
entire four-week study period. All AEs were coded using
the NCI Thesaurus. Compliance was assessed by counting
returned medication sachets. If the patient took <70% of
the scheduled amount of medication intake in Week 4
or <80% over the entire treatment duration, this was
regarded as a major protocol violation.
Statistical analysis
The number of patients to be included in the study was
determined through a priori power calculations. The an-
ticipated on-treatment mean stool frequency was 0.9 ± 0.6
per day in the lactulose treatment group and 1.3 ± 0.7 per
day in the PEG 4000 treatment group. These projections
were derived from a previous comparative study of lactu-
lose and PEG 3350 in chronic constipation in adults [25],no studies in children having been documented at the
time the study protocol was designed. A sample of 42
eligible patients in each treatment group would be re-
quired to detect a difference in mean stool frequency of
40% between the PEG 4000 and lactulose treatment groups
with a power of 80% at a two-sided significance level of
0.05. Assuming a drop-out rate of 16%, it was thus planned
to recruit a total of 50 patients per treatment group.
Three study populations were assessed, namely a safety
population, defined as all patients who received at least
one dose of study medication, an intent to treat (ITT)
population, defined as all patients in the safety population
for whom at least one post-treatment measure of stool fre-
quency was available, and a per protocol (PP) population,
defined as all patients in the ITT population without a
major protocol deviation. The primary efficacy analysis
was performed in the ITT population and a sensitivity
analysis in the PP population. The safety analysis was per-
formed in the safety population.
In the case of premature study discontinuation, the
last data value recorded in the patient diary was assigned
according to the principle of last observation carried for-
ward (LOCF). In the case of missing data for stool on a
given day during any week, the mean of the values on
other days in the same week was used to interpolate the
missing one. For a given week, the mean value was com-
puted only if at least four of the seven daily assessments of
the week in question were documented.
The primary objective of the study was to detect a dif-
ference in stool frequency during the fourth week between
the two treatment groups. Stool frequency during the
fourth week of treatment was assessed across treatment
arms using analysis of covariance (ANCOVA), in which
site and baseline stool frequency (during Week −1) were
treated as covariates. In addition, the 95% adjusted confi-
dence interval for the treatment effect was also estimated.
Interactions between treatment group on the one hand
and site and baseline stool frequency on the other were
estimated.
Because of potential deviations from normality of stool
frequency, (as established by the Kolmogorov-Smirnov
test both on raw and transformed data using log, square
root and Box-Cox transformations), a post hoc sensitivity
analysis was performed to compare the treatment effects
using a generalised estimating equation model with a
Poisson distribution for repeated measures, taking into
account baseline stool frequency, site, treatment, study
period and interactions between treatment and study
period, treatment and site and treatment and baseline
stool frequency.
Stool consistency and ease of stool passage were rated
as change from baseline in one of three categories of
change, namely 0 (harder stools/more difficult passage), 1
(no change from baseline) or 2 (softer stools/easier
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toms (cramps, flatulence and anal irritation) were rated as
0 (decrease from baseline), 1 (no change from baseline) or
2 (increase from baseline). Changes in symptom scores
over time were compared between treatment groups using
a generalised estimating equation model with a negative
binomial distribution. Treatment effect estimates are pre-
sented as relative risks with their 95% confidence interval.
The statistical analysis was performed using SAS soft-
ware Version 9.1.3 (SAS, Raleigh, USA).
Ethics
The study was conducted according to the Declaration of
Helsinki and pertinent national legal and regulatory re-
quirements. The protocol was approved by the appropri-
ate independent ethics committees (the Committee on
Human Rights Related to Researches Involving Human
Subjects, Faculty of Medicine, Ramathibodi Hospital,
Mahidol University, Bangkok, Thailand and the Institu-
tional Review Board of the Maharat Nakhon Ratchasima
Hospital, Nakhon Ratchasima, Thailand). Patient confi-
dentiality was ensured by assigning each subject a study
code that was used in the case report form in place of the
patient’s name. Patients were free to withdraw from the
study at any time for any reason. A parent of all participat-
ing children gave their written informed consent for their
child to participate in the study.
Results
Study population
A total of 88 subjects were enrolled in the study, of whom
44 were randomised in each treatment arm. These consti-
tuted the safety population. One patient randomised to
PEG 4000 did not complete the patient diary and was thusFigure 1 Patient flow through the study.excluded from the ITT population, which consisted of 87
patients. Ten patients in the ITT population (five in each
group) were excluded from the PP population due to
major protocol violations, principally poor compliance.
The flow of patients through the study is illustrated in
Figure 1. The two study centres were evenly balanced (44
patients enrolled in each centre). The mean exposure to
the study treatment was 29.2 ± 1.77 days [median: 29 days;
range: 28 – 39 days] in the lactulose arm and 28.9 ±
5.81 days [median: 29 days; range: 4 – 56 days] in the PEG
4000 treatment arm.
The baseline socio-demographic characteristics of the
study population are shown in Table 1. The mean age was
1.99 ± 0.50 years. Overall, there were more boys than girls
enrolled (56.8% vs. 43.2%). All children enrolled fulfilled
the stool frequency criterion for chronic constipation (≤2
stools/week) and fifteen (seven in the lactulose group and
eight in the PEG 4000 group) also fulfilled the stool
consistency criterion (hard stools most of the time). The
mean duration of chronic constipation was 43.8 ±
25.4 weeks and 53 children (60.2%) had previously been
treated for their constipation with at least one other agent,
principally lactulose (22 children), sodium chloride en-
emas (15 children), liquid paraffin (9 children), glycerine-
based suppositories (8 children) or PEG 4000 (5 children).
The two study groups were well balanced. In particular,
stool frequency at baseline did not differ between the two
groups (p = 0.084; Mann–Whitney U-test).
Primary efficacy outcome
In the ITT population, the mean stool frequency in-
creased from 0.7 stools/day during the baseline period to
0.8 at study end (Week 4) in the lactulose group and
from 0.5 to 1.1 stools/day respectively in the PEG 4000
Table 1 Socio-demographic and clinical characteristics of
patients at the baseline study visit in the enrolled
(safety) population (N = 88)
Lactulose PEG 4000 p
(N = 44) (N = 44)
Gender, n (%)
Boys 24 (54.6%) 26 (59.1%) 0.83
Girls 20 (45.5%) 18 (40.9%) (χ2 test)
Age, years
Mean ± SD 1.98 ± 0.52 1.99 ± 0.50 0.83
Median [range] 2.0 [1–3] 2.0 [1–3] (Student’s t-test)
Duration of chronic
constipation (weeks)
Mean ± SD 44.4 ± 28.8 43.2 ± 21.8 0.73
Median [range] 36 [8–116] 40 [10–104] (Wilcoxon test)
Previous treatment for
chronic constipation
26 (59.1%) 27 (61.4%) 0.99
(χ2 test)
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baseline and site, stool frequency was significantly higher
(p = 0.0005) in the PEG 4000 group than in the lactulose
group during Week 4. The adjusted mean change from
baseline in stool frequency was 0.15 stools/day in the
lactulose group and 0.51 stools/day in the PEG 4000
group, corresponding to a least-squares mean difference
of 0.36 stools/day [95% CI: 0.16 to 0.56]. No significant
treatment × site (p = 0.13) or treatment × baseline stool
frequency (p = 0.66) interactions were observed.
Since stool frequency at baseline did not follow a normal
distribution using either non-transformed or transformed
data (p <0.01; Kolmogorov-Smirnov test), a post hoc ana-
lysis of the data was performed using a generalised estimat-
ing equation model for repeated measures. A significant
difference between the two treatment groups was alsoTable 2 Stool frequency (number of stools per day) in the
ITT population (N = 87) and the PP population (N = 77)
ITT Population Lactulose PEG 4000
(N = 44) (N = 43)
Baseline 0.7 ± 0.5 0.5 ± 0.55
Week 4 (study end) 0.8 ± 0.41 1.1 ± 0.55
Change (Week 4 – Baseline; unadjusted) 0.1 ± 0.55 0.6 ± 0.63
Adjusted difference in mean
change from baseline
0.36 [95% CI: 0.16 to 0.56]
PP Population Lactulose PEG 4000
(N = 39) (N = 38)
Baseline 0.7 ± 0.51 0.5 ± 0.56
Week 4 (study end) 0.8 ± 0.39 1.1 ± 0.56
Change (Week 4 – Baseline; unadjusted) 0.1 ± 0.55 0.6 ± 0.63observed in this model (p <0.001). No treatment × site
interaction was observed. The evolution of stool frequency
over the treatment period is presented in Figure 2. The
higher on-treatment stool frequency in the PEG 4000
group is observed at all time-points, starting from the first
week of treatment.
In the PP population, a treatment × site interaction of
borderline significance (p = 0.0511) was observed and, for
this reason, the treatment effect size was estimated inde-
pendently for each site. At site 1 (Bangkok), the adjusted
mean change from baseline was 0.10 stools/day in the lac-
tulose group and 0.67 stools/day in the PEG 4000 group,
corresponding to a least-squares mean difference of 0.57
stools/day [95% CI: 0.23 to 0.91], which was significant
(p = 0.0016). At site 2 (Nakhon Ratchasima), the adjusted
mean change from baseline was 0.29 stools/day in the lac-
tulose group and 0.47 stools/day in the PEG 4000 group,
corresponding to a least-squares mean difference of 0.17
stools/day [95% CI: −0.087 to 0.432]. This difference did
not reach the statistical significance.
Secondary efficacy outcomes
The secondary efficacy outcomes are summarised in
Table 3. With regard to stool consistency, improvements
in stool consistency scores were higher in the PEG 4000
group than in the lactulose group (p = 0.0012), with a rela-
tive risk of achieving softer stools of 1.27. Compared to
baseline, softer stools were reported at the end of the
study (Week 4) for 58.6% of children. Similarly, stool pas-
sage improved to a greater extent in the PEG 4000 group
than in the lactulose group (p = 0.001), with a relative risk
of achieving easier stools of 1.35. Stool passage was re-
ported as easier for 40.9% of children at Week 4. NoFigure 2 Stool frequency by treatment week. Data are presented
as mean values ± standard deviations. Open symbols: lactulose group;
filled circles: PEG 4000 group.
Table 3 Secondary efficacy outcome measures
(ITT population: N = 87)
Lactulose PEG 4000 Relative risk p




1.27 [1.1 - 1.46] 0.0012
Baseline 1.16 ± 0.83 1.35 ± 0.95
Week 2 1.71 ± 0.88 2.19 ± 0.73




Worsened 6 (13.6%) 6 (14.0%)
No change 11 (25.0%) 13 (30.2%)
Improved 27 (61.4%) 24 (55.8%)
Ease of stool passage
Mean symptom
score ± SD
1.35 [1.13 - 1.62] 0.001
Baseline 0.93 ± 0.95 0.98 ± 0.77
Week 2 1.23 ± 0.86 1.66 ± 0.75




Worsened 6 (13.6%) 4 (9.3%)
No change 21 (47.7%) 20 (46.5%)




0.65 [0.31 - 1.35] 0.25
Baseline 0.71 ± 0.85 0.32 ± 0.64
Week 2 0.36 ± 0.72 0.23 ± 0.36




Decreased 17 (38.6%) 7 (16.3%)
No change 21 (47.7%) 33 (76.7%)




0.87 [0.62 - 1.22] 0.42
Baseline 0.86 ± 0.80 0.63 ± 0.73
Week 2 0.64 ± 0.75 0.70 ± 0.74




Decreased 10 (22.7%) 11 (25.6%)
No change 23 (52.3%) 22 (51.2%)
Increased 11 (25.0%) 10 (23.3%)
Table 3 Secondary efficacy outcome measures




0.33 [0.11 - 1.02] 0.055
Baseline 0.80 ± 1.11 0.54 ± 0.96
Week 2 0.18 ± 0.54 0.09 ± 0.37




Decreased 15 (34.1%) 12 (27.9%)
No change 26 (59.1%) 30 (69.8%)
Increased 3 (6.8%) 1 (2.3%)
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were observed with respect to cramps, flatulence or anal
irritation. The proportion of children for whom the inten-
sity of cramps was modified at the end of treatment, during
Week 4 was different between the two groups (p = 0.02).
The proportion of children with unchanged cramp inten-
sity was higher in the PEG 4000 group than in the lactulose
group, whereas the proportion of patients whose cramps
had worsened, as well as those whose cramps had im-
proved, were both higher in the lactulose group than in
the PEG 4000 group. By Week 4, flatulence had improved
in 24.1% of children and anal irritation in 31.0%. Four chil-
dren in the lactulose treatment group required rescue
treatment with a sodium chloride enema.Safety
Over the course of the study, 55 treatment-emergent ad-
verse events (TEAEs) were reported in 26 children in the
lactulose group (59.1%) and 80 TEAEs reported in 27 chil-
dren in the PEG 4000 group (61.4%). These TEAEs are
summarised in Table 4. The most frequently reported
TEAEs were signs of local irritation of the anus and upper
respiratory tract infections and related terms (rhinitis, pha-
ryngitis, sinusitis, otitis media). The nature and incidence
of individual TEAEs was similar in the two treatment
groups. The majority of these events were considered mild
and none were considered severe.
Five adverse events were considered possibly or prob-
ably related to the study drug, two in the lactulose group
(diarrhoea and fever, both documented in the same infant)
and three in the PEG 4000 group (three cases of diar-
rhoea). Two subjects, both in the PEG 4000 group, experi-
enced TEAEs which led to permanent discontinuation of
the study drug. These cases consisted of one case of
vomiting and diarrhoea and one case of fever and vomit-
ing associated with sinusitis. These two children were sub-
sequently lost to follow-up and withdrawn from the study.
Table 4 Treatment-emergent adverse events (TEAEs)
reported during the course of the study by treatment
group (safety population; N = 88)
Lactulose PEG 4000
(N = 44) (N = 44)
Any TEAE* 26 (59.1%) [55 events] 27 (61.4%) [80 events]
Anal dilation 10 (22.7%) [14 events] 14 (31.8%) [11 events]
Upper respiratory
tract infections
9 (20.5%) [11 events] 9 (20.5%) [11 events]
Anal fissure 5 (11.4%) [6 events] 9 (20.5%) [10 events]
Faecaloma 7 (15.9%) [10 events] 5 (11.4%) [6 events]
Hard faeces 4 (9.1%) [4 events] 3 (6.8%) [3 events]
Anal skin tags 1 (2.3%) [2 events] 5 (11.4%) [5 events]
Rhinorrhoea 1 (2.3%) [1 event] 3 (6.8%) [3 events]
Vomiting None 3 (6.8%) [3 events]
Mild TEAEs 26 (59.1%) [53 events] 26 (59.1%) [72 events]
Moderate TEAEs 1 (2.3%) [2 events] 5 (11.4%) [8 events]




1 (2.3%) [2 events] 3 (6.8%) [3 events]







None 2 (4.6%) [5 events]
Data are presented as the number of patients (%), with the number of events
given in square brackets. *Only individual events reported in more than two
patients in either group are listed.
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were documented. One infant in the lactulose group expe-
rienced a varicella infection, one in the PEG 4000 group a
pneumonia infection and a second in the PEG 4000 group
a road traffic accident. Treatment was temporarily sus-
pended during hospitalisation in the two children with
infections. None of these three serious adverse events
were considered related to the study medication. No
deaths occurred during the course of the study.
Vital signs recorded at each study visit as well as the
physical examination were comparable for the two study
groups.
Discussion
This study performed in Thailand showed PEG 4000 to be
more efficacious than lactulose in increasing stool fre-
quency in young children with chronic constipation and
to be well-tolerated. This finding adds to the growing evi-
dence base that PEG osmotic laxatives are more effective
than lactulose in the treatment of constipation in children
[10,26]. In terms of safety, the tolerability of PEG 4000
was satisfactory and broadly comparable to that oflactulose. Both treatments were well accepted and no
clinically relevant safety issue was identified.
These findings are consistent with those of a large
Chinese study in 216 older children aged from eight to
eighteen years which also demonstrated greater efficacy of
PEG 4000 compared to lactulose [17,18]. A meta-analysis
published by the Cochrane collaboration estimated the on-
treatment difference in stool frequency between patients re-
ceiving PEG preparations and those receiving lactulose to
be 1.09 stools per week [95% CI: 0.02 to 2.17] [26]. Our
findings (on-treatment intergroup difference of 0.3 stools/
day) are towards the upper end of the range of the estimate
of the meta-analysis.
The results of our study also complement those of a
previous one evaluating the safety of PEG 4000 and lactu-
lose in 96 children aged from six months to three years,
performed in France [16]. This study demonstrated the
good long-term safety of PEG 4000, and our findings are
consistent with this. Efficacy was a secondary outcome in
the French study, which found both PEG 4000 and lactu-
lose to be effective in relieving constipation with greater
improvements observed in the PEG 4000 group with re-
spect to stool consistency, appetite, new-onset faecal im-
paction and recourse to enema use. As in this French
study, we were also able to demonstrate a benefit of PEG
4000 over lactulose with respect to stool consistency and
ease of stool passage, although not with respect to associ-
ated symptoms. In the meta-analysis published by the
Cochrane collaboration [26], minor adverse events oc-
curred with similar frequency in children treated with
PEG preparations and with lactulose.
The study has a number of strengths and weaknesses.
The strengths include the randomised, double-blind com-
parative design, which has not been used extensively in
studies of constipation in paediatric populations, the
qualification of the reference centres and the low rate of
study discontinuations and of major protocol violations.
Since the two preparations compared in this study have a
different taste, there was some risk of compromising the
blinding, although the medication was provided in identi-
cal sachets, using an identical dosing regimen. The mean
treatment exposure was high in both groups and the ac-
ceptability of the two preparations was high, with compli-
ance superior to >80% in all but three patients in both
treatment arms. Data collected using a patient diary filled
in by the parents cannot be independently ascertained,
which may compromise their accuracy. However, the use
of a patient diary represents a pragmatic solution to data
collection in the community setting and such patient-
related outcome measures are recommended in current
guidelines for follow-up assessment of bowel habits in
children [27]. In the PP population, but not in the ITT
population, there was an indication of an interaction
between treatment and study centre, with the treatment
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compared to site 2. However, it should be noted that the
change from baseline in stool frequency at site 2 was still
nearly twofold higher in the PEG 4000 group than in the
lactulose group, and that the study was insufficiently pow-
ered to detect significant between-group differences at the
site level. We have no obvious explanation for the treat-
ment × site interaction in the PP population, but this may
possibly relate to the fact that four of the five major proto-
col violations in the lactulose group related to patients en-
rolled at site 2.
The choice of inclusion criteria in this study merits
some comment. At the time the study protocol was being
drawn up, the Rome III criteria for infants [28] had not
been published. We used a modification of the Rome II
criteria for functional constipation in infants and pre-
school children (scybalous, pebble-like, hard stools for a
majority of stools or firm stools two or less times/week,
and no evidence of structural, endocrine, or metabolic dis-
ease present for at least two weeks). We modified the dur-
ation criterion to three months since we did not feel that
treatment of very young children for one month with an
experimental treatment could be justified if the constipa-
tion could be transient or self-resolving. A faecal inconti-
nency criterion was added since this is frequently
associated with functional constipation in children. How-
ever, in the event, no children were included on the basis
of faecal incontinence alone. A longer minimum duration
of symptoms and inclusion of a faecal incontinence criter-
ion are present in the current Rome III criterion [28].
The superiority of PEG preparations over lactulose or
other osmotic laxatives demonstrated in this and other
studies and the limited tolerability of stimulant laxatives in
children confer a favourable benefit-risk relationship on
such preparations. This underlines the recommendations
of current practice guidelines in which PEG preparations
are identified as first-line treatment options. The NASP-
GHAN guidelines [27,29] recommend use of mineral oil (a
lubricant) or magnesium hydroxide, lactulose, sorbitol or
PEG (osmotic laxatives), or a combination of lubricant and
laxative, and state that PEG appears to be superior to other
osmotic agents in palatability and acceptance by children.
The guidelines of the National Institute for Health and
Clinical Excellence (NICE) identify PEG/electrolyte solu-
tions as the recommended first-line treatment [30]. Effect-
ive treatment of children with constipation is important
both to relieve discomfort and distress and to improve
quality of life for patients and their parents. In addition, ef-
fective early management of constipation reduces the risk
of persistence into adolescence and adulthood [7,8], thus
reducing the overall burden and cost of disease from a
public health perspective. For this reasons, the availability
of effective and well-tolerated osmotic laxatives such as
PEG 4000 have an important place in the management ofchronic constipation in young children. A recent Cochrane
review [26] concluded that PEG preparations may be su-
perior to placebo, lactulose and magnesium hydroxide for
the management of childhood constipation, and was asso-
ciated with a lower incidence of adverse events.
Conclusion
This randomised, double-blind comparative study pro-
vides robust and reliable evidence for the superior efficacy
of PEG 4000 over lactulose in the treatment of chronic
constipation in young children. The good safety and ac-
ceptability of PEG 4000 make it a first-line treatment of
choice for young children in order to restore normal
bowel habits.
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